Publications
Selected Publications
Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo J, Colbert LE, Klopp AH. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 Feb 22;4(1):237. doi: 10.1038/s42003-021-01741-x. PubMed PMID: 33619320.
Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G Jr, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 Feb 18;. doi: 10.1038/s41591-020-01224-2. [Epub ahead of print] PubMed PMID: 33603241.
Yang P, Rhea PR, Conway T, Nookala S, Hegde V, Gagea M, Ajami NJ, Harribance SL, Ochoa J, Sastry JK, Cohen L. Human Biofield Therapy Modulates Tumor Microenvironment and Cancer Stemness in Mouse Lung Carcinoma. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420940398. doi: 10.1177/1534735420940398. PubMed PMID: 32975128; PubMed Central PMCID: PMC7522816.Recent publications from the PRIME-TR team:
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020 Dec 10;. doi: 10.1126/science.abb5920. [Epub ahead of print] PubMed PMID: 33303685, Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B.
Gut Microbes' Impact on Oncogenic Drivers: Location Matters. Mol Cell. 2020 Sep 17;79(6):878-880. doi: 10.1016/j.molcel.2020.08.021.PMID: 32946762, White MG, Wargo JA.
Modulating gut microbes. Science. 2020 Sep 11;369(6509):1302-1303. doi: 10.1126/science.abc3965. PMID: 32913089, Wargo JA.
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?, Nat Rev Immunol. 2020 Sep;20(9):522-528. doi: 10.1038/s41577-020-0374-6. Epub 2020 Jul 13. PMID: 32661409, Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L
Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers, Curr Oncol Rep. 2020 Jun 24;22(7):74. doi: 10.1007/s11912-020-00913-y.PMID: 32577835, McQuade JL, Ologun GO, Arora R, Wargo JA.
Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review, Semin Hematol, 2020 Jan;57(1):13-18. doi: 10.1053/j.seminhematol.2020.05.002. Epub 2020 May 19.PMID: 32690139, Halsey T, Ologun G, Wargo J, Jenq RR.
The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 May 29;368(6494):973-980. doi: 10.1126/science.aay9189.PMID: 32467386, Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R.
Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 Mar;65(3):885-896. doi: 10.1007/s10620-020-06111-x.PMID: 32067144, Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA.
AI finds microbial signatures in tumours and blood across cancer types. Nature. 2020 Mar;579(7800):502-503. doi: 10.1038/d41586-020-00637-w. PubMed PMID: 32161344, Ajami NJ, Wargo JA.
Recent publications from the PRIME-TR team:
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020 Dec 10;. doi: 10.1126/science.abb5920. [Epub ahead of print] PubMed PMID: 33303685, Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B.
Gut Microbes' Impact on Oncogenic Drivers: Location Matters. Mol Cell. 2020 Sep 17;79(6):878-880. doi: 10.1016/j.molcel.2020.08.021.PMID: 32946762, White MG, Wargo JA.
Modulating gut microbes. Science. 2020 Sep 11;369(6509):1302-1303. doi: 10.1126/science.abc3965. PMID: 32913089, Wargo JA.
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?, Nat Rev Immunol. 2020 Sep;20(9):522-528. doi: 10.1038/s41577-020-0374-6. Epub 2020 Jul 13. PMID: 32661409, Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L
Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers, Curr Oncol Rep. 2020 Jun 24;22(7):74. doi: 10.1007/s11912-020-00913-y.PMID: 32577835, McQuade JL, Ologun GO, Arora R, Wargo JA.
Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review, Semin Hematol, 2020 Jan;57(1):13-18. doi: 10.1053/j.seminhematol.2020.05.002. Epub 2020 May 19.PMID: 32690139, Halsey T, Ologun G, Wargo J, Jenq RR.
The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 May 29;368(6494):973-980. doi: 10.1126/science.aay9189.PMID: 32467386, Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R.
Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 Mar;65(3):885-896. doi: 10.1007/s10620-020-06111-x.PMID: 32067144, Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA.
AI finds microbial signatures in tumours and blood across cancer types. Nature. 2020 Mar;579(7800):502-503. doi: 10.1038/d41586-020-00637-w. PubMed PMID: 32161344, Ajami NJ, Wargo JA.
Recent publications from the PRIME-TR team:
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020 Dec 10;. doi: 10.1126/science.abb5920. [Epub ahead of print] PubMed PMID: 33303685, Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B.
Gut Microbes' Impact on Oncogenic Drivers: Location Matters. Mol Cell. 2020 Sep 17;79(6):878-880. doi: 10.1016/j.molcel.2020.08.021.PMID: 32946762, White MG, Wargo JA.
Modulating gut microbes. Science. 2020 Sep 11;369(6509):1302-1303. doi: 10.1126/science.abc3965. PMID: 32913089, Wargo JA.
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?, Nat Rev Immunol. 2020 Sep;20(9):522-528. doi: 10.1038/s41577-020-0374-6. Epub 2020 Jul 13. PMID: 32661409, Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L
Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers, Curr Oncol Rep. 2020 Jun 24;22(7):74. doi: 10.1007/s11912-020-00913-y.PMID: 32577835, McQuade JL, Ologun GO, Arora R, Wargo JA.
Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review, Semin Hematol, 2020 Jan;57(1):13-18. doi: 10.1053/j.seminhematol.2020.05.002. Epub 2020 May 19.PMID: 32690139, Halsey T, Ologun G, Wargo J, Jenq RR.
The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 May 29;368(6494):973-980. doi: 10.1126/science.aay9189.PMID: 32467386, Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R.
Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 Mar;65(3):885-896. doi: 10.1007/s10620-020-06111-x.PMID: 32067144, Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA.
AI finds microbial signatures in tumours and blood across cancer types. Nature. 2020 Mar;579(7800):502-503. doi: 10.1038/d41586-020-00637-w. PubMed PMID: 32161344, Ajami NJ, Wargo JA.
Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo J, Colbert LE, Klopp AH. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 Feb 22;4(1):237. doi: 10.1038/s42003-021-01741-x. PubMed PMID: 33619320.
Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G Jr, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 Feb 18;. doi: 10.1038/s41591-020-01224-2. [Epub ahead of print] PubMed PMID: 33603241.
Yang P, Rhea PR, Conway T, Nookala S, Hegde V, Gagea M, Ajami NJ, Harribance SL, Ochoa J, Sastry JK, Cohen L. Human Biofield Therapy Modulates Tumor Microenvironment and Cancer Stemness in Mouse Lung Carcinoma. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420940398. doi: 10.1177/1534735420940398. PubMed PMID: 32975128; PubMed Central PMCID: PMC7522816.
News, Blog Posts and Opinion Pieces
April 21, 2021, the Accelerating Cancer Immunotherapy Research "AICR" attended the AACR conference and selected key talks from the conference including: Dr. Jennifer Wargo, The microbiome and cancer: Minimizing the hype and illuminating the hope talk, https://acir.org/weekly-digests/2021/april/aacr-annual-meeting-2021
May 5, 2020, Oncology Times, Life in the Time of COVID-19, Kantarjian, Hagop MD; Welch, Mary Alma MMSc; Kornblau, Steven MD; DiNardo, Andrew MD; Ajami, Nadim PhD, https://journals.lww.com/oncology-times/Fulltext/2020/05050/Life_in_the_Time_of_COVID_19.2.aspx
April 13, 2020, Baker Institute Blog, LOOKING FOR LIGHT AT THE END OF THE COVID-19 TUNNEL, Hagop Kantarjian, M.D., Mary Alma Welch, Nadim Ajami, Ph.D., http://blog.bakerinstitute.org/2020/04/13/looking-for-light-at-the-end-of-the-covid-19-tunnel/
April 7, 2020, Baker Institute Blog, THE IMPORTANCE OF WIDESPREAD COVID-19 TESTING IN HOUSTON AND THE TEXAS MEDICAL CENTER, Hagop Kantarjian, M.D., Nadim Ajami, Ph.D., Andrew DiNardo, M.D., https://blog.bakerinstitute.org/2020/04/07/the-importance-of-widespread-covid-19-testing-in-houston-and-the-texas-medical-center/
May 5, 2020, Oncology Times, Life in the Time of COVID-19, Kantarjian, Hagop MD; Welch, Mary Alma MMSc; Kornblau, Steven MD; DiNardo, Andrew MD; Ajami, Nadim PhD, https://journals.lww.com/oncology-times/Fulltext/2020/05050/Life_in_the_Time_of_COVID_19.2.aspx
April 13, 2020, Baker Institute Blog, LOOKING FOR LIGHT AT THE END OF THE COVID-19 TUNNEL, Hagop Kantarjian, M.D., Mary Alma Welch, Nadim Ajami, Ph.D., http://blog.bakerinstitute.org/2020/04/13/looking-for-light-at-the-end-of-the-covid-19-tunnel/
April 7, 2020, Baker Institute Blog, THE IMPORTANCE OF WIDESPREAD COVID-19 TESTING IN HOUSTON AND THE TEXAS MEDICAL CENTER, Hagop Kantarjian, M.D., Nadim Ajami, Ph.D., Andrew DiNardo, M.D., https://blog.bakerinstitute.org/2020/04/07/the-importance-of-widespread-covid-19-testing-in-houston-and-the-texas-medical-center/
May 5, 2020, Oncology Times, Life in the Time of COVID-19, Kantarjian, Hagop MD; Welch, Mary Alma MMSc; Kornblau, Steven MD; DiNardo, Andrew MD; Ajami, Nadim PhD, https://journals.lww.com/oncology-times/Fulltext/2020/05050/Life_in_the_Time_of_COVID_19.2.aspx
April 13, 2020, Baker Institute Blog, LOOKING FOR LIGHT AT THE END OF THE COVID-19 TUNNEL, Hagop Kantarjian, M.D., Mary Alma Welch, Nadim Ajami, Ph.D., http://blog.bakerinstitute.org/2020/04/13/looking-for-light-at-the-end-of-the-covid-19-tunnel/
April 7, 2020, Baker Institute Blog, THE IMPORTANCE OF WIDESPREAD COVID-19 TESTING IN HOUSTON AND THE TEXAS MEDICAL CENTER, Hagop Kantarjian, M.D., Nadim Ajami, Ph.D., Andrew DiNardo, M.D., https://blog.bakerinstitute.org/2020/04/07/the-importance-of-widespread-covid-19-testing-in-houston-and-the-texas-medical-center/
May 5, 2020, Oncology Times, Life in the Time of COVID-19, Kantarjian, Hagop MD; Welch, Mary Alma MMSc; Kornblau, Steven MD; DiNardo, Andrew MD; Ajami, Nadim PhD, https://journals.lww.com/oncology-times/Fulltext/2020/05050/Life_in_the_Time_of_COVID_19.2.aspx
April 13, 2020, Baker Institute Blog, LOOKING FOR LIGHT AT THE END OF THE COVID-19 TUNNEL, Hagop Kantarjian, M.D., Mary Alma Welch, Nadim Ajami, Ph.D., http://blog.bakerinstitute.org/2020/04/13/looking-for-light-at-the-end-of-the-covid-19-tunnel/
April 7, 2020, Baker Institute Blog, THE IMPORTANCE OF WIDESPREAD COVID-19 TESTING IN HOUSTON AND THE TEXAS MEDICAL CENTER, Hagop Kantarjian, M.D., Nadim Ajami, Ph.D., Andrew DiNardo, M.D., https://blog.bakerinstitute.org/2020/04/07/the-importance-of-widespread-covid-19-testing-in-houston-and-the-texas-medical-center/
May 5, 2020, Oncology Times, Life in the Time of COVID-19, Kantarjian, Hagop MD; Welch, Mary Alma MMSc; Kornblau, Steven MD; DiNardo, Andrew MD; Ajami, Nadim PhD, https://journals.lww.com/oncology-times/Fulltext/2020/05050/Life_in_the_Time_of_COVID_19.2.aspx
April 13, 2020, Baker Institute Blog, LOOKING FOR LIGHT AT THE END OF THE COVID-19 TUNNEL, Hagop Kantarjian, M.D., Mary Alma Welch, Nadim Ajami, Ph.D., http://blog.bakerinstitute.org/2020/04/13/looking-for-light-at-the-end-of-the-covid-19-tunnel/
April 7, 2020, Baker Institute Blog, THE IMPORTANCE OF WIDESPREAD COVID-19 TESTING IN HOUSTON AND THE TEXAS MEDICAL CENTER, Hagop Kantarjian, M.D., Nadim Ajami, Ph.D., Andrew DiNardo, M.D., https://blog.bakerinstitute.org/2020/04/07/the-importance-of-widespread-covid-19-testing-in-houston-and-the-texas-medical-center/